New Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026
PRESS RELEASE
New Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026
Presentations highlight therapy-induced senescence as a new therapeutic opportunity and reinforce the potential of STX-1 as a differentiated approach for solid tumors
Lille and Villejuif, France, April 16, 2026 – StarkAge Therapeutics, a biotechnology company pioneering first-in-class senolytic antibody-drug conjugates (ADC) for age-related diseases with an initial focus on oncology, today announced that it will present two posters at the AACR Annual Meeting 2026. These data strengthen the company’s leadership in senescence-targeted oncology and support the development of STX-1, its first-in-class DPP4-targeting ADC, as a novel therapeutic strategy for patients with solid tumors who have limited treatment options.
“These AACR presentations underscore the growing recognition that therapy-induced senescence is a key driver of tumor progression and resistance,” said Eric Angevin, MD, PhD, Chief Medical Officer. “By selectively eliminating DPP4-expressing cells in both tumor and stroma, particularly in the context of senescence, STX-1 has the potential to establish a new therapeutic approach for patients with limited treatment options. Our strategy is grounded in a strong translational foundation and aims to address a significant unmet need in solid tumors.”
In the translational poster, StarkAge and Gustave Roussy Institute characterize the impact of treatment-induced senescence in metastatic colorectal cancer and highlight DPP4 (CD26) as a senescence-associated biomarker expressed in both stromal and tumor compartments. The study integrates immunohistochemistry, bulk and single-cell RNA sequencing analyses across large patient datasets and characterize senescence-related biology and its potential implications for disease progression and treatment resistance.
In the preclinical poster, StarkAge will present data showing that STX-1 demonstrated strong affinity for DPP4, high internalization, target-dependent cytotoxicity and in vivo antitumor activity, with enhanced activity in senescent cell-enriched tumors. The abstract also reports that senescence induction through chemo- or radiotherapy increased DPP4 expression, while senescent cancer cells remained sensitive to STX-1 treatment. In vivo, enhanced activity was observed in senescence-enriched tumors, and STX-1 was reported to be well tolerated in toxicology studies in mice expressing human DPP4.
AACR 2026 Poster Details
Preclinical poster
Title: STX-1, a first-in-class ADC targeting DPP4 protein, acts as an anticancer and senolytic treatment
Session / Abstract #: PO.ET02.01 - Antibody-Drug Conjugates and Linker Engineering 1
Presenter: Benjamin Le Calvé, StarkAge Therapeutics
Date / Time: April 20, 2026, 9:00 AM - 12:00 PM
Location: Section 12
Translational poster
Title: Treatment-induced senescence in metastatic colorectal adenocarcinomas: implications for single-cell biology and therapeutic intervention
Session / Abstract #: PO.MCB04.02 - Senescence and Cell Stress
Presenter: Antoine Hollebecque, Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
Date / Time: April 21, 2026, 2:00 PM - 5:00 PM
Location: Section 24
END
About StarkAge Therapeutics
StarkAge Therapeutics is a biotechnology company based in Lille, France, pioneering first-in-class senolytic antibody–drug conjugates (ADCs) to address age-related diseases, with an initial focus on oncology.
About STX-1
STX-1 is StarkAge Therapeutics’ lead DPP4-targeting ADC, designed to combine anticancer and senolytic activity in tumors characterized by DPP4 expression and senescence-associated biology. STX-1 is currently progressing toward IND-enabling studies.
Media Contact
StarkAge Therapeutics
Marie Puvieux – Press Officer, ATCG Partners
Starkage@atcg-partners.com
+33 610 54 36 72
Attachment
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
